ANI Pharmaceuticals (NASDAQ:ANIP) Stock: Insider Stephen Carey Sells 2,850 Shares

Key Points

• CFO Stephen Carey sold 2,850 ANI Pharmaceuticals shares at an average price of $73, generating $208,050. The Rule 10b5-1 transaction reduced his holdings by 1.66%, leaving him with 168,993 shares.
• ANI Pharmaceuticals recently exceeded quarterly expectations, reporting $2.21 in earnings per share versus the $2.04 consensus and $266.04 million in revenue, up 25.8% year over year.
• The stock traded near $72.72, while analysts maintained a consensus “Hold” rating with an average price target of $98. Institutional investors own approximately 76.05% of the company.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CFO Stephen Carey sold 2,850 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $73.00, for a total transaction of $208,050.00. Following the completion of the sale, the chief financial officer owned 168,993 shares of the company's stock, valued at approximately $12,336,489. This trade represents a 1.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Up 0.1%

NASDAQ ANIP traded up $0.10 during trading hours on Wednesday, reaching $72.72. 298,204 shares of the company traded hands, compared to its average volume of 384,030. ANI Pharmaceuticals, Inc. has a 12 month low of $69.58 and a 12 month high of $97.00. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $1.67 billion, a PE ratio of 15.67, a PEG ratio of 2.41 and a beta of 0.45. The company has a 50 day moving average of $75.50 and a two-hundred day moving average of $78.11.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company's revenue was up 25.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current year.

Institutional Trading of ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ANIP. Tidal Investments LLC acquired a new stake in ANI Pharmaceuticals in the second quarter worth $248,000. WINTON GROUP Ltd acquired a new position in shares of ANI Pharmaceuticals during the second quarter valued at $4,558,000. Corient Private Wealth LP grew its position in shares of ANI Pharmaceuticals by 95.2% during the second quarter. Corient Private Wealth LP now owns 24,106 shares of the specialty pharmaceutical company's stock worth $1,995,000 after acquiring an additional 11,754 shares during the last quarter. Amundi grew its position in shares of ANI Pharmaceuticals by 595.5% during the second quarter. Amundi now owns 31,793 shares of the specialty pharmaceutical company's stock worth $2,632,000 after acquiring an additional 27,222 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth about $1,449,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wall Street Zen lowered ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Weiss Ratings lowered ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, August 11th. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 price objective for the company. Oppenheimer started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They set a "market perform" rating and a $85.00 target price for the company. Finally, Guggenheim dropped their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a report on Monday, August 10th. Three research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $98.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI's portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.